$ Value
$0
Shares
16,875,000
Price
$0
Filed
Apr 20
Insider
Name
Bain Capital Life Sciences Investors, LLC
Title
—
CIK
0001703031
Roles
Transaction Details
Transaction Date
2026-04-20
Code
C
Table
Derivative
Ownership
Indirect
Equity Swap
No
Shares After
—
Footnotes
Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. | Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date. | Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments"). | Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Filing Info
Bain Capital Life Sciences Investors, LLC's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-20 | KLRA | C | — |
| 2026-04-20 | KLRA | C | — |
| 2026-04-20 | KLRA | ▲ | $25.0M ★ |
| 2026-04-20 | KLRA | C | $0 |
| 2026-04-20 | KLRA | C | $0 |
Other Insiders at KLRA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Kaplan Andrew T. / BAIN CAPITAL INVESTORS LLC | $134.4M | — | 2026-04-20 |
| Bain Capital Life Sciences Investors, LLC / Koppel Adam | $25.0M | — | 2026-04-20 |
| RTW INVESTMENTS, LP | $8.0M | — | 2026-04-20 |
| BAIN CAPITAL INVESTORS LLC | — | — | 2026-04-20 |
| MILLIGAN JOHN F | — | — | 2026-04-16 |
|
Renaud Ronald C JR
CEO & President
|
— | — | 2026-04-16 |
| MACKAY MARTIN | — | — | 2026-04-16 |
| Koppel Adam | — | — | 2026-04-20 |
|
Pagan Douglas W.
Chief Financial Officer
|
— | — | 2026-04-16 |
| Bain Capital Life Sciences Investors, LLC | — | — | 2026-04-20 |
|
Burgess Paul D.
See Remarks
|
— | — | 2026-04-16 |
|
Cloghessy Paula
Chief People Officer
|
— | — | 2026-04-16 |
| Kaplan Andrew T. | — | — | 2026-04-20 |
| Clyburn Frank | — | — | 2026-04-16 |
| Hite Christopher | — | — | 2026-04-16 |
|
Akamine Scott
Chief Legal Officer
|
— | — | 2026-04-16 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | — | — | 2026-04-20 |
|
Coleman Jamie Beth
Chief Commercial Officer
|
— | — | 2026-04-16 |
|
Wasserman Scott M.
Chief Medical Officer
|
— | — | 2026-04-16 |